PD-L1 antibody (AA 39-191)
-
- Target See all PD-L1 Antibodies
- PD-L1 (CD274 (PD-L1))
-
Binding Specificity
- AA 39-191
-
Reactivity
- Human, Mouse
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This PD-L1 antibody is un-conjugated
-
Application
- Western Blotting (WB), ELISA, Coating (Coat)
- Purification
- Purified by Protein A/G
- Immunogen
- Recombinant fragment of human CD274 protein (around aa39-191) (exact sequence is proprietary)
- Clone
- PDL1-2744
- Isotype
- IgG1 kappa
- Top Product
- Discover our top product PD-L1 Primary Antibody
-
-
- Application Notes
-
Positive Control: Jurkat, HEK293 or HepG2 cells. Lung SqCC, Cervical or Breast Carcinoma.
Known Application: ELISA (For coating, order antibody without BSA),Western Blot (1-2 μg/mL),Optimal dilution for a specific application should be determined.
- Restrictions
- For Research Use only
-
- Concentration
- 200 μg/mL
- Buffer
- 10 mM PBS with0.05 % BSA & 0.05 % azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-80 °C
- Storage Comment
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
- Expiry Date
- 24 months
-
- Target
- PD-L1 (CD274 (PD-L1))
- Alternative Name
- CD274 (PD-L1 Products)
- Synonyms
- B7-H antibody, B7H1 antibody, PD-L1 antibody, PDCD1L1 antibody, PDCD1LG1 antibody, PDL1 antibody, A530045L16Rik antibody, B7h1 antibody, Pdcd1l1 antibody, Pdcd1lg1 antibody, Pdl1 antibody, RGD1566211 antibody, CD274 molecule antibody, CD274 antigen antibody, programmed cell death 1 ligand 2 antibody, CD274 antibody, Cd274 antibody, PDCD1LG2 antibody
- Background
- Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20 % and 15 % identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.
- Molecular Weight
- 37-50kDa
- Gene ID
- 29126
- UniProt
- Q9NZQ7
- Pathways
- Cancer Immune Checkpoints
-